Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference

Rhea-AI Summary

Passage Bio, a clinical stage genetic medicines company focused on neurodegenerative diseases, has announced its participation in Chardan's 8th Annual Genetic Medicines Conference. Will Chou, M.D., the company's president and CEO, will present on Tuesday, October 1, 2024, at 8:30 a.m. ET.

The presentation will be accessible via a live webcast on the Investors & Media section of Passage Bio's website at investors.passagebio.com. For those unable to attend the live event, a replay will be available for 30 days following the presentation.

Passage Bio is traded on the NASDAQ under the ticker symbol PASG.

News Market Reaction – PASG

-5.11%

-5.11% Session move

In the trading session that priced this news, PASG declined 5.11%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Chardan’s 8^th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 8:30 a.m. ET.

A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event.

About Passage Bio

Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.

To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: www.passagebio.com.

For further information, please contact:

Investors:
Stuart Henderson
Passage Bio
267.866.0114
shenderson@passagebio.com

Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
mikebeyer@sambrown.com

FAQ

When is Passage Bio (PASG) presenting at Chardan's 8th Annual Genetic Medicines Conference?

Passage Bio (PASG) is presenting at Chardan's 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024, at 8:30 a.m. ET.

Who will be presenting for Passage Bio (PASG) at the Chardan conference?

Will Chou, M.D., the president and chief executive officer of Passage Bio, will be presenting at the Chardan conference.

How can I watch Passage Bio's (PASG) presentation at the Chardan conference?

You can watch a live webcast of Passage Bio's presentation on the Investors & Media section of their website at investors.passagebio.com.

For how long will the replay of Passage Bio's (PASG) presentation be available?

The replay of Passage Bio's presentation will be available for 30 days following the event.

What is Passage Bio's (PASG) focus as a genetic medicines company?

Passage Bio (PASG) is a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases.